Contributions of Degradation and Brain-to-blood Elimination Across the Blood—Brain Barrier to Cerebral Clearance of Human Amyloid-β Peptide(1-40) in Mouse Brain
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The purpose of the present study was to estimate the relative contributions of degradation and brain-to-blood elimination processes to the clearance of microinjected human amyloid-β peptide(1-40) (hAβ(1-40)) from mouse cerebral cortex, using a solid-phase extraction method together with a newly developed ultraperformance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) quantitation method for intact hAβ(1-40). The clearance rate constant of hAβ(1-40) in mouse cerebral cortex was determined to be 3.21 × 10−2/min under conditions where the saturable brain-to-blood elimination process across the blood–brain barrier (BBB) was expected to be saturated. Thus, this clearance rate constant should mainly reflect degradation. The [125 I]hAβ(1-40) elimination rate across the BBB under nonsaturating conditions was determined to be 1.48 × 10−2/min. Inhibition studies suggested that processes sensitive to insulin and phosphoramidon, which inhibit neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme, are involved not only in degradation, but also in elimination of hAβ(1-40). In conclusion, our results suggest a dominant contribution of degradation to cerebral hAβ(1-40) clearance, and also indicate that a sequential process of degradation and elimination of degradation products is involved in cerebral hAβ(1-40) clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells
Lippmann, E. S., Azarin, S. M., Kay, J. E., Nessler, R. A., Wilson, H. K., Al-Ahmad, A., Palecek, S. P., & Shusta, E. V. (2012) · Nature Biotechnology · doi:10.1038/nbt.2247 · Cited by 800
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders
Caccamo, A., Oddo, S., Sugarman, M. C., Akbari, Y., & LaFerla, F. M. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.013 · Cited by 299
Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo
Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., & Thiele, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031520100 · Cited by 294
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Cited by
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“Indeed, the results of in vitro, in vivo and animal model studies suggest that hECE-1 activity could prevent or delay progression of AD (Eckman andEckman, 2005; Ito et al., 2013; Pacheco-Quinto et al., 2013).”
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., Mauri, M., Cagnotto, A., Colombo, L., Fiordaliso, F., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0284-14.2014 · Cited by 162
Metadata
- Authors
- Ito, S., Matsumiya, K., Ohtsuki, S., Kamiie, J., & Terasaki, T.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2013-08-21
- Volume
- 33
- Issue
- 11
- Pages
- 1770-1777
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2159359271
- Cited by
- 19
- References
- 6
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contributions of Degradation and Brain-to-blood Elimination Across the Blood—Brain Barrier to Cerebral Clearance of Human Amyloid-β Peptide(1-40) in Mouse Brain. https://app.cochat.ai/papers/10.1038/jcbfm.2013.125
- The paper
- Ito, S., Matsumiya, K., Ohtsuki, S., Kamiie, J., & Terasaki, T. (2013). Contributions of Degradation and Brain-to-blood Elimination Across the Blood—Brain Barrier to Cerebral Clearance of Human Amyloid-β Peptide(1-40) in Mouse Brain. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1038/jcbfm.2013.125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.